List of Excipients in Branded Drug LOPERAMIDE HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing LOPERAMIDE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	loperamide hydrochloride	0093-0311	DIMETHICONE
Teva Pharmaceuticals USA Inc	loperamide hydrochloride	0093-0311	FERRIC OXIDE RED
Teva Pharmaceuticals USA Inc	loperamide hydrochloride	0093-0311	FERRIC OXIDE YELLOW
Teva Pharmaceuticals USA Inc	loperamide hydrochloride	0093-0311	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in LOPERAMIDE HYDROCHLORIDE?

# Of NDCs	Excipient
5	ALCOHOL
23	ANHYDROUS CITRIC ACID
20	ANHYDROUS LACTOSE
5	BENZOIC ACID

Loperamide Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: October 12, 2026

Loperamide hydrochloride is an established, low-cost antidiarrheal active with limited regulatory exclusivity and substantial formulation flexibility. Commercial value is concentrated in dosage-form differentiation, taste masking, pediatric and geriatric usability, global private-label supply, and manufacturing efficiency rather than new-molecule patent protection. The strongest opportunities are liquid and orally disintegrating products, unit-dose travel formats, sugar-free formulations, and robust global products that meet varying excipient and labeling requirements.

What is the commercial position of loperamide hydrochloride?

Loperamide hydrochloride is a peripherally acting opioid receptor agonist used to reduce stool frequency and improve stool consistency in acute nonspecific diarrhea and selected chronic diarrhea conditions. At labeled doses, its activity is primarily gastrointestinal because systemic penetration into the central nervous system is limited. High-dose misuse has been associated with serious cardiac toxicity, including QT prolongation and ventricular arrhythmias. [1]

The U.S. market is dominated by generic, store-brand, and branded OTC products. Imodium is the best-known reference brand, while products marketed as loperamide hydrochloride capsules, tablets, chewable tablets, and oral solutions compete mainly on price, convenience, flavor, packaging, and distribution.

Commercial factor	Assessment
Active ingredient	Loperamide hydrochloride
Primary category	OTC antidiarrheal
Main dosage forms	Capsules, tablets, chewable tablets, oral liquids
U.S. regulatory route	OTC monograph and approved product pathways, depending on product
Biosimilar exposure	None; loperamide is a small molecule
Current market barrier	Manufacturing quality, labeling compliance, product performance, distribution
Main differentiation levers	Taste, disintegration, swallowability, dosing accuracy, packaging, excipient tolerability
Patent dependence	Low for the active ingredient; potentially relevant for new formulations or delivery systems

The FDA’s OTC antidiarrheal framework permits loperamide hydrochloride for labeled use under specified conditions, subject to dosage, warning, and age restrictions. [2]

What excipients are used in loperamide hydrochloride products?

Commercial products use different excipient systems according to dosage form, release profile, taste target, and manufacturing process. The active dose is low, which gives formulators significant latitude to build a stable and manufacturable dosage unit.

Immediate-release capsules

Hard gelatin or hypromellose capsules commonly use:

• Lactose or microcrystalline cellulose as a diluent
• Pregelatinized starch or maize starch as a binder and disintegrant
• Colloidal silicon dioxide as a glidant
• Magnesium stearate or stearic acid as a lubricant
• Talc as a processing aid
• Gelatin, hypromellose, titanium dioxide, and colorants for the shell

A representative immediate-release capsule strategy is a direct-blend or dry-granulation process using a soluble or partially soluble diluent, a disintegrant, and a low-level lubricant. The formulation should prioritize rapid drug release without excessive hydrophobic lubrication.

The main technical risk is dose uniformity. Because the loperamide dose is small relative to the capsule fill weight, segregation during blending, transfer, and encapsulation can affect content uniformity. Particle-size matching between the active and major excipients, geometric dilution, and validated blend-hold controls are important.

Tablets and chewable tablets

Compressed tablets may use:

• Mannitol or sorbitol for a cooling mouthfeel
• Microcrystalline cellulose for compactability
• Crospovidone, croscarmellose sodium, or sodium starch glycolate for disintegration
• Povidone as a binder
• Colloidal silicon dioxide as a glidant
• Magnesium stearate as a lubricant
• Flavor systems and sweeteners for chewable products

Mannitol is commercially attractive for chewable products because it provides a relatively clean taste and lower hygroscopicity than many polyols. Sorbitol can improve sweetness and mouthfeel but may increase hygroscopicity and gastrointestinal tolerance concerns at higher excipient loads.

Chewable products require more than rapid disintegration. They need acceptable grittiness, low residual bitterness, controlled chew time, and stable flavor performance. Loperamide hydrochloride can require taste masking because the active has an unpleasant taste profile when released in the mouth.

Oral liquids

Oral solutions and suspensions may contain:

• Purified water
• Glycerin
• Sorbitol solution
• Propylene glycol or polyethylene glycol
• Citric acid or citrate buffers
• Flavoring agents
• Sweeteners
• Preservatives such as methylparaben or propylparaben, where justified
• Suspending agents in products that are not fully solubilized

The commercial advantage of a liquid is dosing flexibility and easier administration for some patients. The disadvantages are preservative requirements, flavor stability, microbial-control obligations, transport weight, and dosing errors.

A clear solution provides a more uniform dose than a suspension, but the formulation must balance pH, solubilization, taste, preservative efficacy, and chemical stability. A suspension can reduce reliance on cosolvents but creates requirements for redispersibility, sedimentation control, and dose uniformity after storage.

What formulation patents protect loperamide hydrochloride products?

The original active-ingredient protection for loperamide hydrochloride is not the principal commercial barrier in the current U.S. market. Loperamide products are generally treated as mature generic and OTC products, with competition focused on formulation execution and regulatory compliance.

Potentially protectable formulation subject matter includes:

Formulation area	Potential claim scope	Commercial value
Orally disintegrating tablets	Rapid disintegration, low friability, taste masking	Moderate
Chewable tablets	Flavor system, polyol matrix, bitterness reduction	Moderate
Oral liquids	Solubilization, preservative system, pH control	Moderate
Modified release	Release control for chronic diarrhea	Selective, but regulatory complexity is higher
Abuse-deterrent products	Gelling, aversive, or dose-limiting systems	Potentially high but difficult to validate
Multiparticulates	Pellet coating, sprinkle dosage forms, dose flexibility	Moderate
Packaging	Unit-dose, child-resistant, senior-friendly systems	Usually design or utility protection rather than core drug patent value
Manufacturing process	Content uniformity, granulation, coating, or drying process	Often valuable as know-how and process IP

Any new patent strategy would need to claim a measurable technical advantage, such as improved dissolution, superior taste masking, extended stability, reduced dose variability, or a clinically meaningful administration benefit. A generic mixture of established excipients is unlikely to provide strong exclusionary value unless the composition has unexpected performance.

When does loperamide hydrochloride lose exclusivity?

Loperamide hydrochloride has already passed the core small-molecule exclusivity period in the United States. The market is therefore open to generic and private-label competition, subject to applicable FDA requirements.

Exclusivity category	Current commercial relevance
New chemical entity exclusivity	Expired
Original composition patent	Expired or no longer commercially controlling
Pediatric exclusivity	No current barrier to ordinary generic competition
Orphan exclusivity	Not the basis of the mainstream loperamide market
Biosimilar exclusivity	Not applicable
OTC monograph protection	Does not create branded market exclusivity
Formulation patent exclusivity	Possible only for separately protected innovations

The practical entry question is not whether the active is available. It is whether a proposed product complies with the relevant OTC monograph, approved labeling, dosage-form requirements, quality standards, and state or national packaging rules.

What is the Orange Book status of loperamide hydrochloride?

The FDA Orange Book primarily concerns approved prescription drug products and related patent and exclusivity information. Many loperamide products are marketed as OTC products under the FDA monograph system rather than as prescription products with an active Orange Book patent dispute structure.

For this reason, an Orange Book search should not be treated as the sole source for evaluating loperamide market entry. The relevant regulatory review should include:

1. FDA OTC monograph requirements.
2. Approved product labeling for reference and comparable products.
3. DailyMed labels and ingredient declarations.
4. FDA establishment and drug-listing information.
5. National regulatory requirements in each target market.
6. Packaging and abuse-related requirements where applicable.

The absence of a material Orange Book patent barrier does not eliminate formulation, manufacturing, trademark, trade dress, or regulatory risks.

Which companies are challenging loperamide hydrochloride products?

Loperamide does not present a concentrated current Paragraph IV challenge landscape comparable with a high-value patented prescription drug. Competition is fragmented across generic manufacturers, OTC marketers, contract manufacturers, and private-label retailers.

Potential competitors include:

• Branded OTC companies selling loperamide products
• Generic drug manufacturers
• Retail pharmacy private-label suppliers
• Contract development and manufacturing organizations
• Regional manufacturers serving Europe, Asia, Latin America, and emerging markets

Paragraph IV litigation is generally not the central entry mechanism for ordinary loperamide products because the active ingredient and basic immediate-release dosage forms are mature. A Paragraph IV dispute could arise if a company obtained a later patent covering a specific formulation, delivery system, or method of use, but that would be a product-specific issue rather than a feature of the basic loperamide market.

What patent litigation and settlement agreements affect loperamide?

There is no widely recognized current patent-litigation structure controlling ordinary loperamide hydrochloride capsules, tablets, or liquids in the U.S. market. The historical brand-versus-generic disputes that commonly affect newer prescription products are not the primary commercial issue here.

Settlement agreements may still arise around:

• Brand trademarks
• Private-label supply rights
• Contract manufacturing
• Product-specific formulation patents
• Packaging designs
• Distribution territories
• Regulatory exclusivity in non-U.S. jurisdictions

For investors and licensees, the more relevant diligence is often freedom to operate around trademarks, package appearance, formulation patents for differentiated products, and supplier agreements rather than an active basic-compound patent.

What excipient strategy offers the strongest commercial opportunity?

Taste-masked chewable and orally disintegrating products

Taste masking is the clearest formulation opportunity. A useful platform may combine:

• Ion-exchange resin or polymeric taste-masking technology
• Coated active particles
• Mannitol-based compression
• High-intensity sweeteners
• Flavors selected for bitterness suppression
• Rapid-disintegration excipients

The product must maintain acceptable dissolution after masking. Excessive coating can delay release and create regulatory questions about bioequivalence or therapeutic performance.

Sugar-free and low-calorie liquids

Sugar-free products using sorbitol, glycerin, or other suitable sweetening systems may appeal to diabetic consumers and broader OTC markets. The key development constraints are preservative efficacy, viscosity, microbial control, and flavor stability.

Pediatric and family-oriented presentations

Pediatric use requires careful compliance with age restrictions, dosing instructions, and warning language. The commercial opportunity is in usability rather than aggressive expansion of the labeled population. Oral syringes, calibrated cups, and single-dose sachets can reduce dosing ambiguity.

The product should avoid creating a presentation that encourages use in children for conditions requiring medical evaluation. FDA labeling restricts use in young children and emphasizes medical attention for certain symptoms, including bloody or black stools and fever. [1,2]

Geriatric-friendly capsules and tablets

Swallowability is a meaningful opportunity. Smaller capsules, smooth coatings, lower-friction tablet surfaces, and orally disintegrating formats can improve administration for older adults. Packaging should support opening without weakening child resistance requirements.

Unit-dose travel formats

Travel diarrhea creates a strong use case for lightweight, portable packaging. Blister packs, foil sachets, and compact kits can support pharmacies, travel retailers, airlines, and institutional channels. The formulation should tolerate temperature and humidity excursions likely to occur during transport.

How does loperamide compare with competing antidiarrheal products?

Product category	Main advantage	Main limitation	Excipient opportunity
Loperamide hydrochloride	Strong stool-frequency control and low cost	Misuse risk; warnings for serious symptoms	Taste masking, safe dosing, travel packaging
Bismuth subsalicylate	Broad OTC recognition and multiple gastrointestinal uses	Salicylate-related warnings and dark stool	Suspension stability, palatability, dose convenience
Oral rehydration solutions	Replaces fluids and electrolytes	Does not directly reduce motility	Flavor, osmolality, portable powder formats
Adsorbent products	Perceived local gastrointestinal action	Variable clinical positioning	Suspension texture and dispersion
Prescription bile-acid or antisecretory therapies	Targeted use in selected chronic conditions	Higher regulatory and clinical burden	Modified release and patient-specific delivery

Loperamide competes most effectively where the consumer prioritizes rapid reduction in stool frequency, compact packaging, and low cost. Oral rehydration products remain important because antidiarrheal therapy does not replace fluid and electrolyte management.

What generic launch risks exist for loperamide hydrochloride?

The main launch risks are operational and regulatory:

1. Incorrect OTC labeling or failure to follow monograph conditions.
2. Dose nonuniformity in low-dose solid products.
3. Slow dissolution caused by excessive lubricant or taste-masking coating.
4. Poor liquid preservative performance.
5. Inadequate redispersibility in suspensions.
6. Inaccurate consumer dosing devices.
7. Packaging that fails child-resistant or senior-friendly requirements.
8. Inadequate warnings concerning high-dose misuse.
9. Cross-border excipient restrictions.
10. Supply disruption for gelatin, colorants, flavors, or specialty polymers.

For global products, excipient selection should begin with a restricted-substance matrix covering FDA, European, Japanese, and target-market requirements. Titanium dioxide, parabens, colorants, propylene glycol, gelatin source, and animal-derived materials may require jurisdiction-specific review.

How strong is the patent estate for loperamide hydrochloride?

The basic patent estate is weak as a barrier to ordinary generic entry because the active ingredient and conventional immediate-release presentations are mature. A new entrant can create stronger protection through a narrow, evidence-backed formulation estate.

A practical formulation patent portfolio could include:

• Composition claims for a defined taste-masked particle system
• Process claims for reproducible low-dose blending
• Dosage-form claims for rapid oral disintegration
• Stability claims tied to a defined pH or preservative system
• Packaging claims for unit-dose or abuse-resistant delivery
• Method claims limited to an approved and clinically supportable use

Trade secrets may be more valuable than patents for blending order, coating parameters, flavor ratios, granulation endpoints, and preservative-control methods. Licensing opportunities are strongest where a developer owns a proven taste-masking, orally disintegrating, or abuse-deterrent platform that can be applied to loperamide and other OTC actives.

What licensing and manufacturing opportunities exist?

The most realistic commercial models are:

Model	Opportunity
Private-label supply	Retailer-specific loperamide capsules, liquids, and chewables
Contract manufacturing	Low-cost regional production for OTC distributors
Platform licensing	Taste masking, ODT, multiparticulate, or abuse-deterrent technology
Co-development	Pediatric liquid or geriatric-friendly dosage form
Geographic licensing	Local rights for branded or private-label products
Institutional supply	Hospitals, travel clinics, military, and humanitarian channels
Combination products	Loperamide with rehydration or travel-health kits, subject to regulatory review

Manufacturing economics favor high-throughput capsules and tablets. Liquids can offer differentiation but require more extensive microbiological and packaging controls. Chewable and orally disintegrating products can command a premium if the taste and mouthfeel are demonstrably better than low-cost standard products.

Key Takeaways

• Loperamide hydrochloride is a mature small-molecule OTC active with no biosimilar risk and limited basic-compound patent protection.
• Commercial differentiation depends on dosage form, taste, dosing convenience, packaging, and global regulatory execution.
• The strongest formulation opportunities are taste-masked chewables, orally disintegrating tablets, sugar-free liquids, unit-dose travel formats, and geriatric-friendly products.
• Low-dose content uniformity and dissolution control are central manufacturing risks.
• OTC monograph compliance and labeling are more important than conventional Orange Book patent strategy for many products.
• A new formulation patent must claim a measurable technical advantage, not merely a routine excipient substitution.
• Platform licensing and private-label manufacturing are more realistic opportunities than licensing the underlying active ingredient.
• High-dose misuse concerns should be addressed through compliant labeling, packaging, and carefully evaluated product design.

FAQs

Is loperamide hydrochloride suitable for an orally disintegrating tablet?

Yes. An orally disintegrating tablet is technically feasible, but taste masking, rapid dissolution, low friability, and dose uniformity must be demonstrated together.

Which excipient is best for loperamide taste masking?

No single excipient is universally best. Coated particles, ion-exchange resins, polymeric barriers, mannitol-based matrices, and sweetener-flavor systems can be evaluated based on dissolution and sensory performance.

Can loperamide hydrochloride be formulated as a pediatric liquid?

It can be formulated as an oral liquid, but pediatric commercialization depends on applicable age restrictions, labeling, dosing accuracy, palatability, preservative performance, and medical-use limitations.

Is an abuse-deterrent loperamide product commercially attractive?

It may be attractive, particularly for a differentiated OTC product, but the formulation must demonstrate that the deterrent mechanism is meaningful, does not impair labeled use, and does not create new safety or regulatory concerns.

What is the most defensible IP strategy for a new loperamide product?

The strongest strategy is usually a layered portfolio combining formulation patents, process know-how, trade secrets, trademarks, packaging rights, and regulatory-compliant product differentiation.

References

1. U.S. Food and Drug Administration. (2018). FDA warns about serious heart problems with high doses of the anti-diarrhea medicine loperamide (Imodium), including doses higher than recommended.
2. U.S. Food and Drug Administration. (2024). 21 C.F.R. Part 335: Antidiarrheal products for over-the-counter human use.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. National Library of Medicine. (2024). DailyMed: Loperamide hydrochloride product labeling.
5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Loperamide hydrochloride monograph.